InvestorsHub Logo
Followers 285
Posts 31200
Boards Moderated 0
Alias Born 07/06/2012

Re: John_Langston post# 131247

Monday, 10/20/2014 7:29:15 PM

Monday, October 20, 2014 7:29:15 PM

Post# of 399845
ROTFLMMFAO - yes I agree with Nasrat

“We could not be more pleased with the top line result from the Human Abuse Liability Study for ELI-200 which confirms the effectiveness of our abuse deterrent technology,” said Nasrat Hakim, President and CEO of Elite Pharmaceuticals. “This successful technology will be the platform for an entire line of opioid products utilizing our proprietary technology. We remain on track to file our first new drug application for ELI-200 by December 2014.”

Fear Uncertainty and Doubt FUD It Ain't Going To Work Here Anymore. Notice the lack of question mark.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News